The DOI matches its Crossref record.
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
Open accessAbstract
OBJECTIVE: To determine the long-term effect of adalimumab on patients with ankylosing spondylitis (AS) who participated in the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS), a randomised, double-blind, placebo controlled, 24-week trial. METHODS: Patients received adalimumab 40 mg every other week (eow) or placebo for 24 weeks in ATLAS. At week 24, patients were switched to open-label adalimumab 40 mg eow. Efficacy measures included 20% improvement in the Assessment in SpondyloArthritis International Society (ASAS) criteria (ASAS20), ASAS40 and ASAS partial remission responses and changes in individual components of the ASAS20 response evaluations, for example, Bath AS Functional Index (BASFI) and Bath AS Disease Activity Index (BASDAI). Two-year interim data were analysed based on the total duration of adalimumab exposure, irrespective of the treatment randomisation group. RESULTS: At 2 years, 255 (82.0%) of the original 311 ATLAS patients continued receiving adalimumab treatment. Improvements in ASAS responses observed in ATLAS were sustained during long-term treatment; 64.5% (200/310) were ASAS20 responders, 50.6% (157/310) were ASAS40 responders and 33.5% (104/310) had maintained ASAS-defined partial remission. Changes in individual ASAS response components were sustained or improved during long-term adalimumab treatment. From ATLAS baseline to 2 years of adalimumab exposure, respectively, BASDAI improved from 6.3 (SD 1.7) to 2.4 (SD 2.3) and BASFI improved from 5.2 (SD 2.4) to 2.9 (SD 2.5). Adalimumab was well tolerated. No cases of tuberculosis, congestive heart failure, lupus-like symptoms, or demyelinating disease were reported. CONCLUSIONS: Adalimumab reduced the signs and symptoms of AS and induced partial remission for up to 2 years. The long-term safety profile was similar to the short-term safety profile. Trial registration information: NCT00085644.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., Deodhar, A., Porter, B., Martin, R., Andersson, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505066 · Cited by 1,029
Self-citation2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Braun, J., van den Berg, R., Baraliakos, X., Boehm, H., Burgos-Vargas, R., Collantes-Estevez, E., Dagfinrud, H., Dijkmans, B., Dougados, M., Emery, P., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.151027 · Cited by 987
Self-citationAdverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
van der Heijde, D., Salonen, D., Weissman, B. N., Landewé, R., Maksymowych, W. P., Kupper, H., Ballal, S., Gibson, E., Wong, R., & the Canadian (M03-606) study group and the ATLAS study group (2009) · Arthritis Research & Therapy · doi:10.1186/ar2794 · Cited by 413
Self-citationVincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Mariette, X., & Marcelli, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356
Metadata
- Authors
- van der Heijde, D., Schiff, M. H., Sieper, J., Kivitz, A. J., Wong, R. L., Kupper, H., Dijkmans, B. A. C., Mease, P. J., & Davis, J. C.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 68
- Issue
- 6
- Pages
- 922-929
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2101141197
- Cited by
- 188
- References
- 0
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. https://app.cochat.ai/papers/10.1136/ard.2007.087270
- The paper
- van der Heijde, D., Schiff, M. H., Sieper, J., Kivitz, A. J., Wong, R. L., Kupper, H., Dijkmans, B. A. C., Mease, P. J., & Davis, J. C. (2009). Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard.2007.087270
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.